Carlos E de Andrea

18PUBLICATIONS
184CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Mar 11, 2026
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

|Nov 13, 2025
The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas.

Alvaro Lopez-Janeiro, Emilia Brizzi, Ignacio Ruz-Caracuel

|May 19, 2025
A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study.

Maria Alsina, Guillermo Villacampa, Carlos de Andrea

|Dec 12, 2024
The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Yaiza Senent, Ana Remírez, David Repáraz

Pageof 3

Frequent Collaborators

9 joint publications

Ignacio Melero

6 joint publications

Alvaro Teijeira

6 joint publications

Pedro Berraondo

6 joint publications

Arantza Azpilikueta